SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Galera Therapeutics, Inc. (GRTX) trades at a trailing P/E of 0.1. Trailing earnings yield is 1,666.67%.
Criteria proven by this page:
- VALUE (100/100, Pass) — P/E is below market average (0.1); earnings yield beats bond yields (1,666.67%).
- Trailing Earnings Yield 1,666.67% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.
Overall SharesGrow Score: 66/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — GRTX
Valuation Multiples
P/E (TTM)0.1
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$1.51
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings Yield1,666.67%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2017 |
$-1.55 |
$0.00 |
$-23.55M |
- |
| 2018 |
$-1.22 |
$0.00 |
$-23.68M |
- |
| 2019 |
$-2.09 |
$0.00 |
$-51.93M |
- |
| 2020 |
$-2.98 |
$0.00 |
$-74.22M |
- |
| 2021 |
$-3.40 |
$0.00 |
$-80.53M |
- |
| 2022 |
$-2.30 |
$0.00 |
$-62.22M |
- |
| 2023 |
$-1.33 |
$0.00 |
$-59.08M |
- |
| 2024 |
$-0.35 |
$0.00 |
$-18.96M |
- |
| 2025 |
$1.51 |
$0.00 |
$149.05M |
- |
